Articles By Anuja Singh
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst…
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
ByFDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040 on 20-25% sustained…
AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?
AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst…
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040 on 20-25% sustained…
AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?
AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…